Following the discovery of activating mutations in EGFR, EGFR tyrosine kinase inhibitors (TKIs) have already been introduced in to the first-line treatment of non-small-cell lung cancer (NSCLC). in the EGFR mutation harmful subgroup (median 1.5 vs. 5.5 months, HR 2.85 [2.05C3.98], 0.001) than chemotherapy . The ultimate finding regarded that EGFR mutation could anticipate the… Continue reading Following the discovery of activating mutations in EGFR, EGFR tyrosine kinase